Cutler Group’s Aldeyra Therapeutics ALDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-1,596
Closed -$6K 4849
2022
Q2
$6K Buy
+1,596
New +$5.49K ﹤0.01% 3543
2022
Q1
Sell
-4,458
Closed -$17.8K 5233
2021
Q4
$17K Sell
4,458
-7,223
-62% -$55.1K ﹤0.01% 3233
2021
Q3
$102K Buy
+11,681
New +$107K ﹤0.01% 1891
2019
Q1
Sell
-19
Closed -$161 3961
2018
Q4
$0 Sell
19
-2,752
-99% -$28.2K ﹤0.01% 3862
2018
Q3
$38K Buy
2,771
+2,071
+296% +$16.8K ﹤0.01% 1783
2018
Q2
$5K Buy
+700
New +$5.58K ﹤0.01% 3067

Other funds holding ALDX

Cutler Group's ALDX Position: Q3 2022 in Review

Cutler Group sold out of Aldeyra Therapeutics (ALDX) in Q3 2022, closing a stake of 1,596 shares — an estimated $6K sold.

Cutler Group first reported a position in ALDX in Q2 2018 and held it in 6 quarters. The position peaked at $102K in Q3 2021. 89 funds tracked by Wall St. Rank hold ALDX as of Q3 2022.

  • Cutler Group reported no remaining Aldeyra Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 1,596 Aldeyra Therapeutics shares in Q3 2022, an estimated $6K.
  • Cutler Group first reported a position in Aldeyra Therapeutics in Q2 2018 and held it in 6 quarters.
  • Cutler Group's Aldeyra Therapeutics position peaked at $102K in Q3 2021.
  • 89 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.